Publicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (25)

2024

  1. Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction: Eligibility Based on Randomized Trials Supporting European and American Guidelines

    American Journal of Medicine, Vol. 137, Núm. 2, pp. 137-146.e10

2023

  1. Differences in clinical outcomes, health care resource utilization and costs in heart failure patients according to left ventricular ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 11, pp. 862-871

  2. Impact of standard modifiable cardiovascular risk factors on 2-year all-cause mortality: Insights from an international cohort of 23,489 patients with acute coronary syndrome

    American Heart Journal, Vol. 264, pp. 20-30

2022

  1. Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 8, pp. 777-785

  2. Primary vs. Secondary Heart Failure Diagnosis: Differences in Clinical Outcomes, Healthcare Resource Utilization and Cost

    Frontiers in Cardiovascular Medicine, Vol. 9

  3. Sex differences in mortality after an acute coronary syndrome increase with lower country wealth and higher income inequality

    Revista Espanola de Cardiologia, Vol. 75, Núm. 5, pp. 392-400

2021

  1. Contemporary economic burden in a real-world heart failure population with Commercial and Medicare supplemental plans

    Clinical Cardiology, Vol. 44, Núm. 5, pp. 646-655

  2. Long-Term Antithrombotic Therapy and Clinical Outcomes in Patients with Acute Coronary Syndrome and Renal Impairment: Insights from EPICOR and EPICOR Asia

    American Journal of Cardiovascular Drugs, Vol. 21, Núm. 4, pp. 471-482

  3. Number of Antithrombotic Drugs Used Early and In-hospital Outcomes in Acute Coronary Syndromes

    Journal of Cardiovascular Translational Research, Vol. 14, Núm. 4, pp. 790-798

2020

  1. Assessment of quality indicators for acute myocardial infarction management in 28 countries and use of composite quality indicators for benchmarking

    European Heart Journal: Acute Cardiovascular Care, Vol. 9, Núm. 8, pp. 911-922

2019

  1. Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry

    European heart journal. Acute cardiovascular care, Vol. 8, Núm. 2, pp. 121-129

  2. Meta-Analysis Design and Results in Real Life: Problem Solvers or Detour to Maze. A Critical Review of Meta-Analysis of DAPT Randomized Controlled Trials

    Cardiovascular Revascularization Medicine, Vol. 20, Núm. 10, pp. 897-906

  3. Predicting two-year mortality from discharge after acute coronary syndrome: An internationally-based risk score

    European Heart Journal: Acute Cardiovascular Care, Vol. 8, Núm. 8, pp. 727-737

  4. Predictors of all-cause mortality and ischemic events within and beyond 1 year after an acute coronary syndrome: Results from the EPICOR registry

    Clinical Cardiology, Vol. 42, Núm. 1, pp. 111-119

  5. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

    The Lancet, Vol. 394, Núm. 10204, pp. 1169-1180

2018

  1. Regional variations in hospital management and post-discharge mortality in patients with non-ST-segment elevation acute coronary syndrome

    Clinical Research in Cardiology, Vol. 107, Núm. 9, pp. 836-844

2017

  1. Characteristics and outcomes of medically managed patients with non-ST-segment elevation acute coronary syndromes: Insights from the multinational EPICOR Asia study

    International Journal of Cardiology, Vol. 243, pp. 15-20

  2. Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study

    Cardiovascular Therapeutics, Vol. 35, Núm. 2

  3. Global geographical variations in ST-segment elevation myocardial infarction management and post-discharge mortality

    International Journal of Cardiology, Vol. 245, pp. 27-34

  4. International patterns of dual antiplatelet therapy duration after acute coronary syndromes

    Heart, Vol. 103, Núm. 2, pp. 132-138